| Mgmt Confidence | High confidence in clinical evidence and commercial strategy for DT120 ODT. |
|---|---|
| Demand Visibility | Targeting millions of patients with GAD and MDD; no new GAD treatments. |
| Margin Trends | Operating expenses consistent with expectations; spending moderated after key clinical readouts. |
| Op. Leverage | Financial strength allows decisive investment in launch preparation without compromising quality. |
| Pricing Power | Anticipated pricing corridor between $30,000 and $75,000 based on Spravato benchmarks. |
| Segment Growth | DT120 Phase 3 met primary endpoints in GAD and MDD studies. |
| New Clients | Engaging interventional psychiatry providers; hired new Head of Patient Advocacy. |
| Capex & Debt | $1.05 billion in cash and investments as of September 30, 2026. |
| Regulatory | Two FDA breakthrough therapy designations; NDA filing targeted for H1 2027. |
| Commentary | Focusing on a supervised treatment model and building commercial infrastructure for launch. |
| New Launches | Planned Phase 3 Haven study in PTSD and DT402 for ASD. |
Growth
Q3 2026 net loss narrowed to $51 million from $67.3 million year-over-year; R&D expenses rose to $46.1 million.
Outlook
NDA filing planned for H1 2027; cash runway extends into 2030 with $1.05 billion available.
Risks
Management avoided specific details on pre-NDA meeting outcomes and the exact filing strategy for MDD indications.
The company's earnings call, NASDAQ: DFTX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Definium Therapeutics, Inc.: key numbers
- Share price
- $29.38Close, Nov 17
- Market cap
- $4.02B
- Shares outstanding
- 136.9MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Medicinal Chemicals & Botanical ProductsSIC 2833
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Definium Therapeutics, Inc.
All →Definium Therapeutics Q3 2026 Results: Net Loss of $51M, Loss Narrows
Definium Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing psychedelic-based treatments like DT120 (LSD) and DT402 (MDMA) for psychiatric disorders. As of November 2, 2026, the company had 136,899,935 common shares outstanding and is currently conducting Phase 3 clinical programs for generalized anxiety disorder and major depressive disorder.
- Key figure
- Net loss $51M
Definium Therapeutics Financial Results
Definium Therapeutics reported Q3 2026 financial results, highlighting a strong cash position of $1.05 billion. The company achieved positive Phase 3 topline results for DT120 ODT in generalized anxiety disorder and received FDA Breakthrough Therapy Designation for the same candidate in major depressive disorder.
- Term
- Q3 2026
“Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions.”
Rob Barrow, Chief Executive Officer
“With Breakthrough Therapy designation in MDD and Ascend progressing, we continue to advance our late-stage program while building the capabilities needed to prepare for potential approval and commercialization. Beyond DT120, we believe DT402 represents an exciting opportunity and its initial results support continued development as we work to deliver differentiated therapies for patients with significant unmet needs.”
Rob Barrow, Chief Executive Officer
Definium Therapeutics CFO Brandi Roberts Sells $123K of Stock
Brandi Roberts, CFO, sold 3,377 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $123K in total on Sep 25, 2026. Shares held after the trade: 394,528 (-0.8%).
- Value
- $123K
- Shares
- 3,377
- Price
- $36.57
- Role
- CFO
- Holding change
- -0.8%
- Trade date
- Sep 25, 2026
Definium Therapeutics CLO Mark Sullivan Sells $514K of Stock
Mark Sullivan, CLO, sold 14,051 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $514K in total on Sep 25, 2026. Shares held after the trade: 494,228 (-2.8%).
- Value
- $514K
- Shares
- 14,051
- Price
- $36.57
- Role
- CLO
- Holding change
- -2.8%
- Trade date
- Sep 25, 2026
Definium Therapeutics Chief Commercial Officer Matthew T. Wiley Sells $113K of Stock
Matthew T. Wiley, Chief Commercial Officer, sold 3,097 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $113K in total on Sep 25, 2026. Shares held after the trade: 359,036 (-0.9%).
- Value
- $113K
- Shares
- 3,097
- Price
- $36.57
- Role
- Chief Commercial Officer
- Holding change
- -0.9%
- Trade date
- Sep 25, 2026
Definium Therapeutics CEO Robert Barrow Sells $1.15M of Stock
Robert Barrow, CEO, sold 31,550 shares of Definium Therapeutics, Inc. at $36.57 a share, worth $1.15M in total on Sep 25, 2026. Shares held after the trade: 2,213,090 (-1.4%).
- Value
- $1.15M
- Shares
- 31,550
- Price
- $36.57
- Role
- CEO
- Holding change
- -1.4%
- Trade date
- Sep 25, 2026